Advocacy intelligence hub — real-time data for patient organizations
Vrije Universiteit Brussel — NA
Oils4Cure — PHASE3
David M. Ritter — NA
Darcy Krueger — PHASE2
IRCCS Azienda Ospedaliero-Universitaria di Bologna — NA
Katarzyna Kotulska — PHASE2, PHASE3
Beijing Children's Hospital — NA
Novartis Pharmaceuticals — PHASE3
National Heart, Lung, and Blood Institute (NHLBI) — NA
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Everolimus
(EVEROLIMUS)Orphan drugstandardBreckenridge Pharmaceutical, Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the PI3K/AKT pat...
Epidiolex
(CANNABIDIOL)Orphan drugstandardJazz Pharmaceuticals, Inc.
12.1 Mechanism of Action The precise mechanisms by which EPIDIOLEX exerts its anticonvulsant effect in humans are unknown. Cannabidiol does not appear...
Hope Northrup, MD, M.D
The University of Texas Medical School at Houston
📍 HOUSTON, TX
Mary Kay Koenig, MD
The University of Texas Medical School at Houston
📍 Houston, Texas
Orrin Devinsky, MD, M.D
NYU Langone Health
📍 NEW YORK, NY
Martina Bebin, MD, MPA
University of Alabama at Birmingham
Katarzyna Kotulska-Jozwiak
The Children's Memorial Health Institute
Martina Bebin, MD
University of Alabama at Birmingham